[1-ethoxy-butylidene]-carbamic acid ethyl ester | 83483-29-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: [1-ethoxy-butylidene]-carbamic acid ethyl ester
• 英文别名: [1-Ethoxy-but-ylidene]-carbamic acid ethyl ester；ethyl N-ethoxycarbonylbutanimidate
• CAS: 83483-29-8
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: QKPNLYBYQXUGBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [1-ethoxy-butylidene]-carbamic acid ethyl ester 在 sodium hydride 、 三乙胺 作用下， 反应 4.33h， 生成
  参考文献：
  名称：

  Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones

  摘要：

  A series of 2,4-dihydro-2,4,5-trisubstituted-3H-1,2,4-triazol-3-ones was prepared via several synthetic routes and evaluated as AII receptor antagonists in vitro and in vivo. The preferred compounds contained a [2'-(5-tetrazolyl)biphenyl-4-yl]methyl side chain at N4 and an n-butyl group at C5. A number of these bearing an alkyl or aralkyl substituent at N2 showed in vitro potency in the nanomolar range (rabbit aorta membrane receptor), and several of these, e.g., the 2,2-dimethyl-1-propyl analogue (54, IC50 = 2.1 nM), effectively blocked the AII pressor response in conscious rats with significant duration (2.5 h at 1 mg/kg orally for 54). Among analogues possessing aryl substituents at N2, ortho substitution on the phenyl moiety resulted in several derivatives with in vitro potency in the low nanomolar range. One of these, featuring a 2-(trifluoromethyl)phenyl substituent at N2 (25, IC50 = 1.2 nM), was effective at 1 mg/kg orally in the rat model, with a duration of >6 h. Implications for hydrophobic and hydrogen-bonding interactions with the AT1 receptor are discussed.

  DOI：

  10.1021/jm00069a015
• 作为产物：
  描述：

  丁酰亚氨酸乙酯 盐酸盐 、 氯甲酸乙酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.25h， 生成 [1-ethoxy-butylidene]-carbamic acid ethyl ester
  参考文献：
  名称：

  WO2007/100295

  摘要：

  公开号：

文献信息

• Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT1 Receptor Affinity and Enhanced AT2 Affinity
  作者：Wallace T. Ashton、Linda L. Chang、Kelly L. Flanagan、Steven M. Hutchins、Elizabeth M. Naylor、Prasun K. Chakravarty、Arthur A. Patchett、William J. Greenlee、Tsing-Bau Chen

  DOI：10.1021/jm00043a020

  日期：1994.8

  cycloalkylcarbonyl derivatives. Certain other acidic sulfonamides, such as sulfonylcarbamates and disulfimides also displayed high affinity for the AT1 receptor. In addition, AT2 binding for some of these compounds was increased by as much as 1000-fold over the corresponding tetrazole (e.g., AT2 IC50 17 nM for the tert-butyl sulfonylcarbamate 92). When evaluated for inhibition of the AII pressor response, the benchmark

  几个系列的2,4-二氢-2,4,5-三取代的3H-1,2,4-三唑-3-酮在联苯-4-基甲基的2'-位上被四唑的酸性磺酰胺取代制备N4链并作为血管紧张素II（AII）拮抗剂进行测试。三唑啉酮环上的优选取代基是在C5处的正丁基和在N2处的2-（三氟甲基）苯基。对于多种酰基磺酰胺，包括芳酰基，杂芳酰基和环烷基羰基衍生物，观察到AT1受体亚型的亚纳摩尔IC50值。某些其他酸性磺酰胺，如磺酰氨基甲酸酯和二硫化亚胺也对AT1受体表现出高亲和力。另外，这些化合物中某些化合物的AT2结合量比相应的四唑增加了1000倍（例如，叔丁基磺酰基氨基甲酸酯92的AT2 IC50 17 nM）。当评估抑制AII升压反应时，基准苯甲酰磺酰胺9（L-159,913）在几种物种中均有效，在有意识的恒河猴中优于氯沙坦（1a）。随后的几种类似物，包括2-氯苯甲酰基（18），（3-氯噻吩-2-基）羰基（51），（（S）-2,2
• A NEW REACTION OF AZIDOFORMATE WITH UNSATURATED ETHERS CATALYZED BY DICHLORO-BIS(BENZONITRILE)PALLADIUM
  作者：Toshihiko Migita、Nobuhiro Saitoh、Hisao Iizuka、Chikataka Ogyu、Masanori Kosugi、Setsuko Nakaido

  DOI：10.1246/cl.1982.1015

  日期：1982.7.5

  In the presence of dichloro-bis(benzonitrile)palladium, azidoformate reacts with various unsaturated ethers to give 1-alkoxy-1-carboalkoxyiminoalkanes. Reaction with 1-methyl-2-propenyl ether was accompaied by methyl migration, giving 1-alkoxy-1-carboalkoxyimino-2-methylpropane.

  在二氯双（苄腈）钯存在下，叠氮甲酸酯与各种不饱和醚反应生成 1-烷氧基-1-碳烷氧基亚氨基烷烃。与1-甲基-2-丙烯基醚的反应伴随着甲基迁移，得到1-烷氧基-1-碳烷氧基亚氨基-2-甲基丙烷。
• Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors
  申请人：Gupta Ramesh Chandra

  公开号：US20100010035A1

  公开（公告）日：2010-01-14

  The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.

  本发明涉及一种新的化合物，其化学式为[应在此处插入化学式。请参见纸质副本]，其中R1、R2、R3和R31如本文所述。本发明还涉及一种制备该化合物的方法，以及新化合物与先前已知药剂的组合。本发明还涉及上述化合物和组合物的用途，用于制备治疗不同类型的高血压、缓解不同类型的器官损伤、治疗或预防糖尿病肾病、治疗内皮素和血管紧张素介导的疾病以及治疗前列腺癌的药物。
• WO2007/100295
  申请人：——

  公开号：——

  公开（公告）日：——
• Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones
  作者：Linda L. Chang、Wallace T. Ashton、Kelly L. Flanagan、Robert A. Strelitz、Malcolm MacCoss、William J. Greenlee、Raymond S. L. Chang、Victor J. Lotti、Kristie A. Faust

  DOI：10.1021/jm00069a015

  日期：1993.8

  A series of 2,4-dihydro-2,4,5-trisubstituted-3H-1,2,4-triazol-3-ones was prepared via several synthetic routes and evaluated as AII receptor antagonists in vitro and in vivo. The preferred compounds contained a [2'-(5-tetrazolyl)biphenyl-4-yl]methyl side chain at N4 and an n-butyl group at C5. A number of these bearing an alkyl or aralkyl substituent at N2 showed in vitro potency in the nanomolar range (rabbit aorta membrane receptor), and several of these, e.g., the 2,2-dimethyl-1-propyl analogue (54, IC50 = 2.1 nM), effectively blocked the AII pressor response in conscious rats with significant duration (2.5 h at 1 mg/kg orally for 54). Among analogues possessing aryl substituents at N2, ortho substitution on the phenyl moiety resulted in several derivatives with in vitro potency in the low nanomolar range. One of these, featuring a 2-(trifluoromethyl)phenyl substituent at N2 (25, IC50 = 1.2 nM), was effective at 1 mg/kg orally in the rat model, with a duration of >6 h. Implications for hydrophobic and hydrogen-bonding interactions with the AT1 receptor are discussed.